@article {7725,
	title = {Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies.},
	journal = {Int J Nanomedicine},
	volume = {10},
	year = {2015},
	month = {2015},
	pages = {4099-109},
	abstract = {<p>The expectations of nanoparticle (NP)-based targeted drug delivery systems in cancer, when compared with convectional therapeutic methods, are greater efficacy and reduced drug side effects due to specific cellular-level interactions. However, there are conflicting literature reports on enhanced tumor accumulation of targeted NPs, which is essential for translating their applications as improved drug-delivery systems and contrast agents in cancer imaging. In this study, we characterized biodegradable NPs conjugated with an anti-CD20 antibody for in vivo imaging and drug delivery onto tumor cells. NPs{\textquoteright} binding specificity mediated by anti-CD20 antibody was evaluated on MEC1 cells and chronic lymphocytic leukemia patients{\textquoteright} cells. The whole-body distribution of untargeted NPs and anti-CD20 NPs were compared by time-domain optical imaging in a localized human/mouse model of B-cell malignancy. These studies provided evidence that NPs{\textquoteright} functionalization by an anti-CD20 antibody improves tumor pharmacokinetic profiles in vivo after systemic administration and increases in vivo imaging of tumor mass compared to non-targeted NPs. Together, drug delivery and imaging probe represents a promising theranostics tool for targeting B-cell malignancies.</p>},
	issn = {1178-2013},
	doi = {10.2147/IJN.S78995},
	author = {Capolla, Sara and Garrovo, Chiara and Zorzet, Sonia and Lorenzon, Andrea and Rampazzo, Enrico and Spretz, Ruben and Pozzato, Gabriele and N{\'u}{\~n}ez, Luis and Tripodo, Claudio and Macor, Paolo and Biffi, Stefania}
}
